Due Diligence Report following Recent Upgrades - BrokerBank Securities
NEW YORK, Sept. 14, 2015 /PRNewswire/ -- PR Newswire - Zaks Investment Research has just recently upgraded (OTCQB: EKSO), leaping over the middle 'hold' rating and moving it directly from a sell to a buy status.
The stock closed on Friday at $1.30 per share, down 3%, following the recommendation on September 11, 2015. Ekso Bionics is based in Richmond, California, also has a buy rating from HC Wainwright, proclaimed several months ago, with a target price of $3. Reuters Research weighs in with an outperform rating.
The company, a manufacturer and developer of wearable, human bionic eksoskeletons that have applications in healthcare, military and consumer markets, has a current annualized growth rate of over 204%, and counts Lockheed Martin as a major client. Revenues in the last quarter grew to $2.5M, a 57% increase over the same period last year.
For a more in-depth due diligence report investors should use the following link at no cost.
http://bit.ly/_EKSO_Due_Diligence_Report
Copy and paste to browser may be required.
About Ekso Bionics Holdings, Inc.
Ekso Bionics is pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This release and report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this release have not been compensated in any form by any source. A full disclaimer can be found by viewing due diligence. We are only human and may make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.
Share this article